12,693 Shares in Pfizer Inc. (NYSE:PFE) Bought by Fi3 FINANCIAL ADVISORS LLC

Fi3 FINANCIAL ADVISORS LLC purchased a new position in shares of Pfizer Inc. (NYSE:PFE) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 12,693 shares of the biopharmaceutical company’s stock, valued at approximately $337,000.

Other large investors have also recently bought and sold shares of the company. Nordea Investment Management AB boosted its stake in Pfizer by 36.1% during the 4th quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company’s stock worth $108,002,000 after purchasing an additional 1,080,822 shares during the period. Parsons Capital Management Inc. RI increased its holdings in Pfizer by 118.7% during the 4th quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company’s stock valued at $7,820,000 after acquiring an additional 159,984 shares in the last quarter. NFJ Investment Group LLC increased its holdings in Pfizer by 12.8% during the 3rd quarter. NFJ Investment Group LLC now owns 384,571 shares of the biopharmaceutical company’s stock valued at $11,129,000 after acquiring an additional 43,719 shares in the last quarter. Daiwa Securities Group Inc. increased its holdings in Pfizer by 25.9% during the 3rd quarter. Daiwa Securities Group Inc. now owns 804,522 shares of the biopharmaceutical company’s stock valued at $23,283,000 after acquiring an additional 165,611 shares in the last quarter. Finally, Copley Financial Group Inc. purchased a new stake in shares of Pfizer during the third quarter worth about $577,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Up 0.1 %

Shares of PFE stock opened at $26.20 on Friday. The stock has a market cap of $148.61 billion, a price-to-earnings ratio of 18.58, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The firm’s 50 day moving average price is $26.17 and its two-hundred day moving average price is $27.05.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business’s quarterly revenue was up 24.7% on a year-over-year basis. During the same quarter last year, the firm posted $0.10 earnings per share. On average, analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on PFE shares. Bank of America reiterated a “neutral” rating and set a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. UBS Group lowered their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a report on Wednesday, January 8th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a report on Tuesday. Citigroup lowered their price target on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Finally, Truist Financial lowered their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $31.92.

Insider Buying and Selling

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.06% of the company’s stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.